Solidus Biosciences Inc.
This article was originally published in Start Up
Why are fewer drugs obtaining market approval in recent years? The answer is likely complex, but toxicology issues may be part of the problem. Solidus Biosciences aims to provide pharmaceutical companies with the tools it needs for early stage tox screening. Its MetaChip, short for Metabolizing Enzyme Toxicology Assay chip, is a high through-put biochip capable of screening compounds for their toxicological and metabolic properties in a single test run.
You may also be interested in...
Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.
At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.
Cure Therapeutics hopes to help the millions of athletes and workers who suffer from tendonitis. The company is developing transdermally delivered nitric oxide drugs designed to lessen the pain and speed recovery from chronic musculoskeletal conditions like swimmer's shoulder, tennis elbow, jumper's knee, and Achilles tendonitis.